Illumina
Global leader in DNA sequencing and array-based technologies, providing instruments, consumables, and software for genomic analysis across research, clinical, and applied markets. Publicly traded on NASDAQ (ILMN).
Notes
Illumina is the dominant global leader in DNA sequencing technology, with an estimated 80%+ market share in next-generation sequencing. The company's sequencing platforms (including NovaSeq, NextSeq, and MiSeq) and consumables are essential infrastructure for genomics research, clinical diagnostics, and consumer genetics.
Founded in 1998 and headquartered in San Diego, Illumina went public in 2000 and has grown to become one of the most valuable life science tools companies globally. The company has consistently driven down the cost of genome sequencing, enabling the "$1,000 genome" and beyond.
In 2023, Illumina faced significant challenges including an FTC order to divest its acquisition of Grail (liquid biopsy company) and activist investor pressure leading to CEO change. The company appointed Jacob Thaysen as CEO in late 2023 to navigate these challenges.
Team
- Jacob Thaysen, Ph.D. - CEO (since November 2023)
- Previously President of Life Sciences at Agilent Technologies
- Francis deSouza - Former CEO (2016-2023)
- Jay Flatley - Former CEO (1999-2016) & Executive Chairman
Additional Research Findings
- Founded in 1998, headquartered in San Diego, California
- Public company on NASDAQ (ticker: ILMN) since 2000
- Market cap ~$20-30 billion (varies)
- ~80% market share in next-generation sequencing
- Revenue over $4 billion annually
- Key platforms: NovaSeq X, NextSeq 1000/2000, MiSeq, iSeq
- ARCH Venture Partners was early investor
- Acquired Grail in 2021, ordered to divest by FTC in 2023
- Approximately 10,000 employees globally
- Key competitors: Thermo Fisher, PacBio, Oxford Nanopore
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| ARCH Venture Partners | Chicago, USA | biotech-focused | seedseries-a+3 | 6 |